Keri Vishakh C, Arunan Bharathi, Kodan Parul, Soneja Manish, Nischal Neeraj, Varadarajan Ashwin, Didwania Akansha, R L Brunda, Aggarwal Anivita, Jorwal Pankaj, Kumar Arvind, Ray Animesh, Sethi Prayas, Meena Ved Prakash, Khanna Puneet, Singh Akhil Kant, Aggarwal Richa, Soni Kapil Dev, Goyal Alpesh, Das Animesh, Trikha Anjan, Wig Naveet
Infectious Diseases, Department of Medicine & Microbiology, All India Institute of Medical Sciences, New Delhi, India.
Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
Ther Adv Vaccines Immunother. 2022 Aug 9;10:25151355221115009. doi: 10.1177/25151355221115009. eCollection 2022.
COVID-19 infections among severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-vaccinated individuals are of clinical concern, especially in those requiring hospitalization. Such real-world data on ChAdOx1 nCoV-19- and BBV152-vaccinated individuals are scarce. Hence, there is an urgent need to understand their clinical profile and outcomes.
A 1:1 pair-matched study was performed among vaccinated and unvaccinated COVID-19 patients admitted between March 2021 and June 2021 at a tertiary care centre in New Delhi, India. The vaccinated group (received at least one dose of ChAdOx1 nCoV-19 or BBV152) was prospectively followed till discharge or death and matched [for age (±10 years), sex, baseline disease severity and comorbidities] with a retrospective group of unvaccinated patients admitted during the study period. Paired analysis was done to look for clinical outcomes between the two groups.
The study included a total of 210 patients, with 105 in each of the vaccinated and unvaccinated groups. In the vaccinated group, 47 (44.8%) and 58 (55.2%) patients had received ChAdOx1 nCoV-19 and BBV152, respectively. However, 73 patients had received one dose and 32 had received two doses of the vaccine. Disease severity was mild in 36.2%, moderate in 31.4% and severe in 32.4%. Two mortalities were reported out of 19 fully vaccinated individuals. All-cause mortality in the vaccinated group was 8.6% (9/105), which was significantly lower than the matched unvaccinated group mortality of 21.9% (23/105), = 0.007. Vaccination increased the chances of survival (OR = 3.8, 95% CI: 1.42-10.18) compared to the unvaccinated group.
In the second wave of the pandemic predominated by delta variant of SARS CoV-2, vaccination reduced all-cause mortality among hospitalized patients, although the results are only preliminary.
在接种严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗的个体中发生新型冠状病毒肺炎（COVID-19）感染备受临床关注，尤其是在那些需要住院治疗的患者中。关于接种ChAdOx1 nCoV-19疫苗和BBV152疫苗个体的此类真实世界数据稀缺。因此，迫切需要了解他们的临床特征和结局。
在印度新德里一家三级医疗中心，对2021年3月至2021年6月期间收治的接种和未接种COVID-19疫苗的患者进行了1:1配对研究。对接种组（接受至少一剂ChAdOx1 nCoV-19或BBV152）进行前瞻性随访直至出院或死亡，并与研究期间收治的未接种疫苗患者的回顾性队列进行匹配（按年龄（±10岁）、性别、基线疾病严重程度和合并症）。对两组之间的临床结局进行配对分析。
该研究共纳入210例患者，接种组和未接种组各105例。在接种组中，分别有47例（44.8%）和58例（55.2%）患者接种了ChAdOx1 nCoV-19和BBV152。然而，73例患者接种了一剂疫苗，32例患者接种了两剂疫苗。疾病严重程度为轻度的占36.2%，中度的占31.4%，重度的占32.4%。在19例全程接种疫苗的个体中有2例死亡。接种组的全因死亡率为8.6%（9/105），显著低于匹配的未接种组死亡率21.9%（23/105），P = 0.007。与未接种组相比，接种疫苗增加了生存机会（OR = 3.8，95%CI：1.42 - 10.18）。
在以SARS-CoV-2德尔塔变异株为主导的第二波疫情中，尽管结果只是初步的，但接种疫苗降低了住院患者的全因死亡率。
